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ABSTRACT
Background A proteolytic imbalance has been
implicated in the development of “classical” chronic lung
disease of prematurity (CLD). However, in “new” CLD this
pattern has changed. This study examines the
longitudinal relationship between neutrophil proteinases
and their inhibitors in ventilated preterm infants and their
relationship to microbial colonisation.
Methods Serial bronchoalveolar lavage ﬂuid was
obtained from ventilated newborn preterm infants.
Neutrophil elastase (NE) activity, cell counts,
metalloproteinase (MMP)-9, MMP-9/TIMP-1 complex,
SerpinB1 concentration and percentage of SerpinB1 and
a1-antitrypsin (AAT) in complex with elastase were
measured. The presence of microbial genes was
examined using PCR for 16S rRNA genes.
Results Statistically more infants who developed CLD
had NE activity in at least one sample (10/20) compared
with infants with resolved respiratory distress syndrome
(RDS) (2/17). However, NE activity was present in
a minority of samples, occurring as episodic peaks. Peak
levels of MMP-9, MMP-9/TIMP-1 complex, percentage
of AAT and SerpinB1 in complex and cell counts were all
statistically greater in infants developing CLD than in
infants with resolved RDS. Peak values frequently
occurred as episodic spikes and strong temporal
relationships were noted between all markers. The peak
values for all variables were signiﬁcantly correlated to
each other. The presence of bacterial 16S rRNA genes
was associated with the development of CLD and with
elevated elastase and MMP-9.
Conclusion NE activity and MMP-9 appear to be
important in the development of “new” CLD with both
proteinase and inhibitor concentrations increasing
episodically, possibly in response to postnatal infection.
INTRODUCTION
Chronic lung disease of prematurity (CLD, also
called bronchopulmonary dysplasia, BPD) causes
ongoing respiratory morbidity and mortality in
preterm infants
1 2 and is associated with large
oversimpliﬁed alveoli suggesting aberrant lung
development (sometimes called “new” CLD/BPD).
3
Inﬂammation is a hallmark in the development of
CLD, with neutrophils and macrophages releasing
reactive oxygen species and proteolytic enzymes
including the serine proteinase neutrophil elastase
(NE)
4 and matrix metalloproteinases including
MMP-9.
56Normally, any free proteinase is effec-
tively neutralised by proteinase inhibitors. Tissue
inhibitors of matrix metalloproteinases (TIMPs) are
regulators of MMPs, which for MMP-9 in the lung is
primarily TIMP-1.
5e7 For NE, the best characterised
is a1-antitrypsin (AAT) with which it forms an
irreversible covalent 1:1 complex; other proteinase
inhibitorsincludesecretoryleukoproteinaseinhibitor
(SLPI), elaﬁn, a2-macroglobulin and SerpinB1 (origi-
nally called monocyte neutrophil elastase inhibitor)
which rapidly binds covalently with NE. SerpinB1
has been studied in rat and mouse models and in
newbornbaboonsbutnotinhumanpreterminfants.
Early studies reported proteolytic imbalance in
preterm infants developing classical CLD.
8e10
“New” CLD shows a different pattern with elastase
activity being less frequently reported.
11e15 An
imbalance between MMP-9 and TIMP-1 has also
been described, but the importance of MMP-9 in the
development of CLD remains unclear.
5e71 6 e18
The aims of this study were (1) to serially measure
NE, AAT, SerpinB1, MMP-9 and MMP-9/TIMP-1
complex in bronchoalveolar lavage (BAL) ﬂuid of
preterm infants at risk of developing CLD; (2) to
examine the relationships between these variables
and their relationship with CLD development; and
(3) to correlate enzyme dysregulation with bacterial
colonisation as identiﬁed by the presence of bacterial
16S ribosomal RNA (rRNA) genes.
METHODS
Patient groups
Three groups of mechanically ventilated infants
were studied: (1) preterm infants (<32 weeks
gestation) who developed mild, moderate or severe
CLD using National Institute of Child Health
criteria
1; (2) preterm infants who developed and
recovered from neonatal respiratory distress
syndrome (RDS); and (3) a control group comprising
term infants who required ventilation for non-respi-
ratory reasons needing #28% oxygen throughout the
study period. Participants were recruited from the
neonatal unit at the University Hospital of Wales,
Cardiff between May 2005 and December 2006.
Bronchoalveolar lavage
BAL was performed as previously described.
19 20
BAL ﬂuid was collected daily for the ﬁrst weekof life
then twice a week until 28 days of age or until
extubation. Two aliquots of 1 ml/kg normal saline
were instilled and suctioned immediately. Samples
were centrifuged at 1000g for 10 min at 48C within
30 min of collection. The supernatant was aliquoted
and stored at  808C. Pelleted cells were resuspended
in phosphate buffered saline, counted with
a haemocytometer and cytospins were stained with
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Paediatric lung diseaseDiff-Quik for cell differential counts. The unused cell suspension
was recentrifuged and the pellet stored at  808C.
NE activity
NE activity in BAL ﬂuid was measured by the kinetic conversion
of Suc-Ala-Ala-Pro-Val-pNA (Bachem, St Helens, UK), as
described previously.
11 14 The speciﬁcity of free NE activity was
veriﬁed by neutralisation with recombinant AAT (Arriva Phar-
maceuticals, Alameda, California, USA).
AAT analysis
The protein concentration in BAL ﬂuid was determined using
a BCA Protein Assay Kit (Pierce, Rockford, Illinois, USA). BAL
ﬂuid AAT was analysed by western blot analysis with equal
protein load as described elsewhere
13 using horseradish per-
oxidase (HRP)-conjugated goat polyclonal anti-human AAT
(AB7635; Abcam PLC, Cambridge, UK). Excess puriﬁed NE
(0.5 mg) was added to BAL ﬂuid for 30 min at room temperature
prior to western blot analysis when immunoreactive native AAT
was observed coincident with NE activity to test speciﬁcity.
SerpinB1 analysis
SerpinB1 was assessed in equal volumes of BAL ﬂuid by western
blot analysis using a rabbit polyclonal anti-SerpinB1 primary
and an HRP-conjugated goat anti-rabbit secondary antibody.
21 A
standard curve (3e30 ng) of recombinant SerpinB1 was included
on each gel. SerpinB1 was quantiﬁed by densitometry using
ImageJ software (http://rsb.info.nih.gov/ij/).
Total MMP-9 and MMP-9/TIMP-1 complex
These were measured by ELISA (R&D Systems, Minneapolis,
USA) according to the manufacturer’s instructions.
Bacterial 16S rRNA analysis
Cell pellet DNA was isolated using the Qiagen RNA/DNA Mini
kit (Qiagen, Crawley, UK). PCR was used to amplify the 16s
rRNA gene using the primers 27f (59-AGAGTTTGATC(AC)
TGGCTCAG-39) and 1492r (59-TACGG(CT)TACCTTGTTAC-
GACTT-39).
22 23 The integrity of extracted DNAwas assessed by
amplifying human mitochondrial cytochrome oxidase (HMCO)
using speciﬁc primers. PCR products were separated on 0.7%
agarose gels stained with ethidium bromide and visualised in
a BioDoc-IT UV Transilluminator (Ultra-Violet Products,
Cambridge, UK).
Sequencing of 16s rRNA genes
Amplicons from samples positive for 16s rRNA genes were puriﬁed
using a Novagen spin-prep PCR clean-up kit (Merck Chemicals,
Nottingham, UK) and sequenced using the BigDye Terminator
V3.1 cycle sequencing kit (Applied Biosystems, Warrington, UK)
and an ABI Prism 3130xl Genetic Analyzer (Applied Biosystems).
Sources of bacterial 16S rRNA genes were determined by amplicon
sequence comparison using the BlastN website.
Statistical methods
Statistical analysis was performed using SPSS V.15.0. The
ManneWhitney U test was used for non-parametric data and
correlations between groups were performed using Spearman
correlation coefﬁcients. The presence of NE or 16s rRNA genes
between groups was compared using c
2 tests. p Values of <0.05
were considered statistically signiﬁcant.
RESULTS
Patients
Forty-two infants of <32 weeks’ gestational age were recruited:
20 developed CLD (5 mild, 12 moderate, 3 severe CLD); 17
recovered from RDS; 5 infants died before they could be classiﬁed
and were excluded from the analysis; there were also 6 term
controls (table 1). Two hundred and twenty BAL ﬂuid samples
were collected: 130 from the CLD group, 45 from the RDS group,
22 from infants who died and 23 from term controls. The median
BAL ﬂuid yield was 50% (IQR 38e63%).
Cell counts
Median (IQR) peak cell counts in BAL ﬂuid were statistically
greater in infants developing CLD (6.75310
6 cells/ml;
3.54e17.9310
6) than in the RDS group (2.22310
6 cells/ml;
1.05e5.50310
6,p ¼0.002) and controls (0.63310
6 cells/ml;
0.156e1.26310
6,p <0.001). The moderate/severe CLD group
(6.30310
6 cells/ml; 3.97e11.3310
6) had a statistically greater
peak cell count than the RDS group (p¼0.005). Neutrophils
dominated the cell counts but macrophages and some epithelial
cells were observed. Peak neutrophil counts were statistically
greater in infants developing CLD (3.36310
6 cells/ml;
1.79e9.93310
6) than in infants with resolved RDS
(1.14310
6 cells/ml; 0.65e2.88310
6,p ¼0.005) and term controls
(0.38310
6 cells/ml; 0.048e0.63310
6,p ¼0.001). Infants with
moderate/severe CLD (2.56310
6 cells/ml; 1.91e7.13310
6) had
statistically more neutrophils than the RDS group.
Elastase activity
Free NE activity was detected in 26/198 BAL ﬂuid samples
(13%). Statistically more infants who developed CLD (10/20)
had free NE activity in at least one BAL ﬂuid sample compared
with the RDS group (2/17, p¼0.013) or controls (0/6, p¼0.027).
Three of 5 infants with mild CLD had detectable NE in at least
one BAL ﬂuid sample. More infants with moderate/severe CLD
had free NE detected in BAL ﬂuid than infants in the RDS group
(p¼0.035). No statistical difference was noted between the RDS
and control groups. No sample from the term controls had free
NE activity. NE activity was present in 23/129 (18%) lavages
from the infants developing CLD and in 3/46 (7%) samples from
infants with resolved RDS.
Detection of NE activity was episodic, with the day of ﬁrst
occurrence varying from days 2 to 26 (median 7 days), and NE
activity coincided with increased BAL ﬂuid cell counts (ﬁgure 1
and online data supplement). In all cases, NE activity was
blocked by the addition of exogenous recombinant AAT (data not
shown), suggesting an imbalance between proteinases and
proteinase inhibitors.
Table 1 Patient characteristics
Chronic lung
disease
Resolved
respiratory
distress
syndrome Term control
Number of patients 20 17 6
Number of samples 130 45 23
Gestational age (weeks) 27
(25
+4e29
+3)*
28
+6
(27e29
+2)*
Term
Birth weight (g) 835
(695e1025)
1120
(935e1315)
2550
(2090e2825)
M:F 11:9 10:7 3:3
Vaginal:caesarean delivery 10:10 6:11 5:1
Antenatal steroids
>24 h
16/20 (80%) 12/17 (71%) 0/6 (0%)
Surfactant therapy 20/20 (100%) 17/17 (100%) 0/6 (0%)
Prolonged rupture of membranes
(>24 h)
4/20 (20%) 1/17 (6%) 0/6
Length of ventilation (days) 7 (5.5e11) 1 (1e4.5) 3
* Values are shown as median (IQR).
Superscript numbers indicate the number of days in addition to gestation in weeks.
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Paediatric lung diseasea1-Antitrypsin
Western blotting detected free AAT as a 53 kDa band, AAT-
proteinase complex at 80 kDa and apparent degraded AAT at
48 kDa (ﬁgure 2A). AAT-NE complex was detected in 18/20
(90%) infants who developed CLD, which is statistically more
than 8/17 (47%) infants whose RDS resolved (p¼0.004). The
maximum percentage of complexed AATas estimated by densi-
tometry was statistically greater for infants in the CLD group
(median 22%; IQR 13e32%) than for infants whose RDS
resolved (median 0; 0e19%, p¼0.012) and term controls (median
0; 0e9%, p¼0.003), and between the RDS group and infants
with moderate/severe CLD (median 22%; 13.5e33.5%, p¼0.013).
Interestingly, BAL ﬂuid collected from some infants with CLD
contained both free NE and unbound AAT (53 kDa) (ﬁgure 2B).
In all cases when a molar excess of NE was incubated with the
BAL ﬂuid prior to western blot analysis, the unbound AAT
(53 kDa) formed a complex with NE or was degraded.
SERPINB1
The median (IQR) SerpinB1 concentration on the ﬁrst day of life
was 155 ng/ml (64e414), which did not increase signiﬁcantly
over the ﬁrst 5 days of life; no statistical difference was noted
between the CLD and RDS groups over this period. Median
(IQR) peak SerpinB1 concentrations were not statistically
different between groups (CLD group: 400 ng/ml; 185e2130;
RDS group: 205 ng/ml; 113e480, p¼0.161) and term controls
(163 ng/ml; 78e164, p¼0.107). No statistical difference was seen
between peak SerpinB1 concentrations in the RDS group and
infants with moderate/severe CLD (455 ng/ml; 191.5e2130,
p¼0.157). Episodic increases in SerpinB1 were observed more
frequently in infants developing CLD than in a minority of RDS
infants (ﬁgure 3), and these increased SerpinB1 episodes corre-
sponded to episodic increases of cell counts, free NE and NE-AAT
complexes (ﬁgure 1 and online supplement). Statistically more
infants with CLD had covalently complexed SerpinB1 in at least
one BAL ﬂuid sample (11/20) compared with infants with
resolved RDS (3/17), p¼0.020. SerpinB1 complex was not
observed in control infants.
MMP-9
Median (IQR) peak MMP-9 protein concentrations were statisti-
callygreaterininfantswhodevelopedCLD(763 ng/ml;200e1790)
than in infants in the RDS group (47 ng/ml; 20e352, p¼0.004)
and term controls (74 ng/ml; 36e250, p¼0.007). Infants with
moderate/severe CLD (948 ng/ml; 252e2322) also had statisti-
cally greater MMP-9 than those with RDS (p¼0.005). Peak MMP-
9/TIMP-1 complex concentrations were greater in infants who
developed CLD (29.9 ng/ml; 13.1e51.3) than in the RDS group
(1.5 ng/ml; 0.9e24.1, p¼0.004) and than infants with moderate/
severe CLD (29.9 ng/ml; 16.5e51.3) than in infants in the RDS
group (p¼0.017). Differences between CLD and term infants
(7.0 ng/ml; 1.4e24.2) were not statistically signiﬁcant (p¼0.068).
Relationship between variables
Strong correlations were observed between most peak values,
particularly MMP-9 and MMP-9/TIMP-1 complexes and NE
activity relative to the percentage of complexed SerpinB1 (table
2). In addition, there were strong temporal correlations between
cell counts, proteinases and anti-proteinases (ﬁgure 1 and online
supplement).
Bacterial 16S rRNA genes
DNA was extracted from 198 BAL ﬂuid samples and satisfactory
DNA integrity was conﬁrmed in 162 by HMCO ampliﬁcation
by PCR (only three infants failed to have a satisfactory sample
DNA). Bacterial 16S rRNA genes were detected in 75/162 (46%)
of these samples; statistically more infants who developed CLD
had 16S rRNA genes in their BAL ﬂuid at some point (14/19,
74%) than infants in the RDS group (5/16 (31%), p¼0.012) or
term controls (2/5 (40%), p¼0.155). Statistically more infants
with moderate/severe CLD (11/14, 79%) had 16s rRNA genes
detected than infants in the RDS group (p¼0.001). Elastase
activity was found in greater numbers of 16S rRNA gene-positive
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Figure 1 Longitudinal analysis of bronchoalveolar lavage ﬂuid from three infants showing temporal relationships between variables. Graphs AeC show
SerpinB1 concentrations (left axis, solid line) and the proportion of a1-antitrypsin (AAT) in complex with serine protease (right axis, broken line) relative
to day of life (x-axis). Graphs DeF show the same infants with matrix metalloproteinase (MMP)-9 concentrations (left axis, solid line) and total cell
counts (right axis, broken line) against days of life. The arrows indicate the days when free neutrophil elastase (NE) was detected. No free NE was
detected in infant 3.
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Paediatric lung diseaselavages (19/75, 25%) than 16S rRNA gene-negative lavages (5/87
(6%), p¼0.009). Furthermore, elastase activity was higher in the
16S rRNA gene-positive lavages than in the negative lavages
(although the median value for both was zero, p¼0.0018). The
median (IQR) total BAL ﬂuid MMP-9 concentration was greater
in 16S rRNA gene-positive lavages (211 ng/ml; 64e1047) than in
16S rRNA gene-negative samples (44 ng/ml; 21e115, p<0.001).
PCR amplicon sequencing showed that the samples with the
greatest NE activity and total MMP-9 concentrations contained
virulent organisms such as Stegastes aureus and E coli (ﬁgure 4A),
while the RDS infants with free elastase and the highest MMP-9
concentrations had organisms regarded as being less virulent such
as S epidermidis (ﬁgure 4B).
DISCUSSION
This study provides a detailed proﬁle of NE and its inhibitors,
AAT (SerpinA1) and SerpinB1 as well as MMP-9 and MMP-9/
TIMP-1 complex in ventilated preterm infants. It identiﬁed
relationships between proteolytic enzymes and their inhibitors
and highlights the importance of postnatal infection in
proteinase release and in the development of CLD.
OurstudyisthemostdetailedlongitudinalanalysistodateofNE
activity in CLD and includes the previously unstudied SerpinB1.
Previous studies examined NE at single time points
11 13 14 or
examined a limited number of samples.
12 15 We found that NE
activity was episodic and frequently occurred relatively late in the
development of CLD, which may cause NE activity to be missed
when summary data are presented rather than longitudinally for
individual infants. BAL ﬂuid studies of intubated infants prevent
comparisons with patients with RDS at equivalent time points.
However, our data suggesting that infection may lead to dysre-
gulated inﬂammation are in agreement with published evidence
that prolonged mechanical ventilation commonly results in the
development of pneumonia.
24
Some infants developed CLD without NE activity being
detected. It is possible that NE activity occurred between lavages
or following extubation. Also, NE activity may be increased in
the pericellular environment as suggested by the presence of
complexed AATand SerpinB1. These complexes, which may be
regarded as surrogate markers for regulated NE release, were
present in far more samples than was free NE, particularly in
infants developing CLD, suggesting successful regulation of
proteinases. The simultaneous presence of free NE and unbound
AAT (53 kDa) was interesting. This may reﬂect oxidation of the
AATreactive site methionine residue resulting in a decreased rate
of NE-AAT complex formation.
25 Thus complex formation
occurred after in vitro incubation for a further 30 min with excess
NE. Alternatively, increased proteinases including MMP-9 may
degrade and inactivate AAT leading to more NE activity. Infec-
tion may trigger this dysregulation as it was closely correlated
with the increased NE.
SerpinB1 has not been studied in human newborn infants but
has been examined in a baboon CLD model.
26 Higher NE activity
was reported in baboons with “classical” compared with “new”
CLD. Baboons developing “new” CLD had 2.5 times the level of
SerpinB1 mRNA in BAL ﬂuid compared with term controls,
while “classical” CLD was associated with lower SerpinB1
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Figure 2 Western blot of a1-antitrypsin (AAT) species in sequential
bronchoalveolar lavage (BAL) ﬂuid specimens for (A) a representative
infant from the resolved respiratory distress syndrome group in whom
active neutrophil elastase (NE) was not detected and (B) an infant from
the chronic lung disease of prematurity group in whom active NE was
detected. Patient age and NE concentrations are shown below each lane
of the western blot. Equal amounts of protein were loaded for analysis
and the left lanes show puriﬁed plasma AAT migrating at 53 kDa
(standard). Additional bands in BAL ﬂuid specimens are the complex with
serine proteases at 80 kDa and degraded AAT at 48 kDa. Note that the
day 1 samples for both infants contain free AAT only, while day 5 BAL
ﬂuid for patient A and days 2e6 for patient B also contain an additional
higher AAT-proteinase complex. BAL ﬂuid from days 2e6 of patient B
also contains degraded AAT.
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Figure 3 Western blot of SerpinB1 species in sequential broncho-
alveolar lavage (BAL) ﬂuid specimens of an infant with chronic lung
disease of prematurity in whom active neutrophil elastase (NE) was
detected. Equal volumes of BAL ﬂuid were loaded for analysis and the left
lane shows puriﬁed SerpinB1 (10 ng) migrating at 42 kDa (standard).
Other species present in BAL ﬂuid are the 66 kDa complex with serine
proteinase, a partially degraded intermediate product and degraded
SerpinB1 at 38 kDa. A statistically signiﬁcant increase in both the total
concentration and percentage in the complex is seen, occurring with
increased NE activity.
Table 2 Correlation coefﬁcients between maximum values of cell
counts, neutrophil elastase (NE) activity, matrix metalloproteinase
(MMP)-9 concentrations, SerpinB1 concentrations, percentage
a1-antitrypsin (AAT) and SerpinB1 in complex and MMP-9/TIMP-1
concentrations in BAL ﬂuid from ventilated newborn infants
Maximum value Maximum value
Spearman’s
correlation
coefﬁcient
(p value)
Log10 MMP-9 Log10 MMP-9/TIMP-1 0.94
Log10 elastase % SerpinB1 in complex 0.88
Log10 SerpinB1 % SerpinB1 in complex 0.76
Log10 MMP-9 Log10 cell count 0.75
Log10 elastase Log10 neutrophil count 0.71
Log10 neutrophil count % SerpinB1 in complex 0.70
Log10 elastase Log10 SerpinB1 0.68
Log10 elastase Log10 cell count 0.65
Log10 elastase Log10 MMP-9 0.65
% AAT in complex % SerpinB1 in complex 0.64
% AAT in complex Log10 elastase 0.62
Log 10 neutrophil count Log10 SerpinB1 0.62
Log 10 cell count Log10 SerpinB1 0.59
Statistical analysis for all correlations shown were statistically signiﬁcant at p<0.001.
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Paediatric lung diseaseconcentrations. We thus hypothesised that a higher SerpinB1
content in“new” CLD may reduce NE activity in human patients
and we did ﬁnd a trend towards higher SerpinB1 levels in infants
with CLD than in those with RDS and controls. Temporal rela-
tionships were noted between SerpinB1 concentration, active NE
and the percentage of SerpinB1 complexed with proteinase,
which suggests that the SerpinB1 increase was part of a protec-
tive mechanism to regulate NE activity.
AAT is an acute phase reactant.
27 Merritt et al
8 showed that
the AAT concentration almost doubled in lung lavages from
infants developing classical CLD. However, we have shown that
the SerpinB1 concentration increased locally and rapidly in
association with increased NE activity. Moreover, the increase in
SerpinB1 was far greater (>10-fold increase for some neonates,
ﬁgure 3) than has previously been described for AAT
8 and may be
more important in neutralising NE activity. The mechanisms of
SerpinB1 release are unknown as the protein lacks an N-terminal
classical secretion sequence.
28 The BAL ﬂuid concentration of
SerpinB1 correlated well with inﬁltrating inﬂammatory cells,
particularly neutrophils (which contain the highest concentra-
tion of SerpinB1); therefore, SerpinB1 may have been released
following cell death or by a non-classical mechanism. However,
the possibility of SerpinB1 upregulation and release cannot be
discounted.
29 Our ﬁnding of SerpinB1 increasing in parallel with
inﬂammation is in keeping with those reported in patients with
cystic ﬁbrosis where a similar correlation between SerpinB1 levels
and neutrophil numbers was also noted.
30
The simultaneous episodic increases of neutrophils, proteinases
(NEandMMP-9)andanti-proteinases(AATandSerpinB1)indicate
a triggered inﬂammatory process leading toanincreased likelihood
of developing CLD; postnatal infection was the most likely
candidate to trigger the inﬂammation. The role of postnatal
infection in the development of CLD is recognised
31 32 but is
frequently underrated. Conventional culture techniques of BAL
ﬂuid are confounded by frequent administration of broad-spec-
trum antibiotics in these patients. Microbial infection or coloni-
sation has previously been conﬁrmed by identiﬁcation of 16S
rRNA genes.
33e35 Our ﬁnding of 16S rRNA genes detection in
patients developing CLD lends further support to postnatal
infection being integral in the pathogenesis of CLD. NE was
detectedmorefrequentlyandinhigherlevelsforBALﬂuidsamples
when 16S rRNA genes were detected. This suggests that infection
rather than microbialcolonisation of the airways is responsible for
episodic spikes of protective proteinases and inhibitors.
Previous studies of MMP-9 have reported conﬂicting results.
Dik et al
17 showed an increased MMP-9 concentration on days 2
and 4 of life in infants with RDS compared with those with
CLD, but Sweet et al
5 and Ekekezie et al
6 found no statistical
difference in MMP-9 levels between groups although both
reported a higher ratio of MMP-9 to TIMP-1 in the BAL ﬂuid of
infants with CLD. Danan et al
7 showed that MMP-9 concen-
trations, primarily ofinactive pro-MMP-9, were increased early in
life, but no difference was noted between infants with CLD and
those with RDS. Studies of baboons found higher MMP-9
concentrations in extremely premature animals with CLD.
16 Our
longitudinal study of human infants suggests that MMP-9 may
be important in the development of CLD and, as with NE, the
increased concentrations were episodic. MMP-9/TIMP-1
concentrations in neonatal BAL ﬂuid have not been reported
previously. We found a strong correlation between total MMP-9
and MMP-9/TIMP-1 complex concentrations; however, only
a small proportion of total MMP-9 appeared to be in complex
with TIMP-1. Furthermore, western blot analysis of our BAL
ﬂuid (data not shown) showed that more than half of the MMP-9
was present as dimer rather than monomer, which may interfere
with TIMP-1 binding, and the mass of the monomer MMP-9
appeared to be mostly present as the pro-enzyme form. Our
ﬁnding of an increased MMP-9 concentration in 16S rRNA
gene-positive samples suggests that the episodic spikes observed
in proteinase concentrations is probably due to infective
episodes.
The sequencing data suggest that, while a number of organ-
isms may be associated with high peaks of elastase and MMP-9,
those infants who develop CLD had more virulent organisms
within their BAL ﬂuid. S aureus and E coli were particularly
prominent in infants with CLD with BAL ﬂuid elastase present,
while the higher proteinase activity in the BAL ﬂuid of infants
whose RDS resolved was associated with S epidermidis, which is
frequently dismissed as a commensal.
In conclusion, our study gives a detailed longitudinal proﬁle
of NE and MMP-9 and their inhibitors AAT and SerpinB1 as
well as MMP-9/TIMP-1 concentrations in the lungs of
preterm infants. It showed that episodic peaks of both
proteinases and their inhibitors occurred, which may be impor-
tant in the development of CLD, and we suggest that postnatal
infection is a crucial trigger for inﬂammatory inﬁltration and
proteinase release leading to lung injury resulting in CLD
development.
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Figure 4 Scatterplots of (A) peak
elastase activity and (B) matrix
metalloproteinase (MMP)-9
concentrations for each diagnostic class
of infant. Filled symbols indicate 16S
rRNA gene-positive specimens and
empty boxes indicate negative
specimens. Sequencing data for 16S
rRNA gene-positive organisms are also
shown. Some samples were identiﬁed
as 16S rRNA gene-positive but no
speciﬁc microorganism was identiﬁed
by sequencing. Abbreviations for micro-
organisms include S epi (S epidermidis),
S haem (S haemolyticus) and P aeru
(P aeruginosa). CLD, chronic lung disease
of prematurity; RDS, respiratory distress
syndrome.
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